BOEHRINGER-INGELHEIM
13.5.2020 14:02:08 CEST | Business Wire | Press release
Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
“Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The prospect of losing one’s sight is frightening. We are committed to transformational therapies that have the potential to succeed in preserving the health and vision of patients with retinal diseases, such as geographic atrophy.”
Utilizing antibody fragment-based technology, which retains the specificity of an antibody while significantly reducing the size of the molecule, may have significant advantages over traditional large molecule approaches for the treatment of retinal diseases, such as GA. When applied to the eye via intravitreal injection, high affinity antibody fragment therapies have the potential to reach the retinal pigment epithelial cells where degeneration is known to occur. This precise technology may help decrease the cellular stresses caused by AMD and prevent further loss of sight.
“Boehringer Ingelheim is one of the leading research and development companies in the field of biologics,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “This is an exciting partnership that brings together Boehringer Ingelheim’s development expertise and CDR-Life’s innovative antibody fragments to provide hope for people living with a blinding retinal disease. We look forward to advancing this project towards the clinic together with the Boehringer Ingelheim team.”
Boehringer Ingelheim takes a holistic approach to the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. By leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases, the company has built a comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
CDR-Life´s preclinical program utilizing antibody fragment-based technology complements this growing portfolio, providing an innovative approach to treat GA.
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop certain compounds based on CDR-Life´s technology against a specific target and will be responsible for global development and commercialization. CDR-Life will be eligible to receive up to CHF 474.5 million in upfront and success-based milestone payments, as well as research funding and royalties on sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/geographicatrophycollabortationwithcdr-life
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Presents its Value Report 2025: change in motion31.3.2026 10:30:00 CEST | Press release
The company’s annual disclosure unveils its Value Plan 2030+ Philip Morris International (NYSE: PM) today released its Value Report 2025, offering a holistic perspective on the company’s approach to sustainable value creation. The report marks the completion of PMI’s 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company’s continued path to sustainable growth. “For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success,” said Jacek Olczak, Group Chief Executive Officer. “‘change in motion’ captures the reality that transformation is not a project with a defined end date, it is the continuous work of improvement, innovation, and adaptation that keeps us relevant and resilient. We transform continuously because markets evolve
BarmeniaGothaer Modernizes Front-to-Back Investment Platform with Bloomberg and Clearwater Analytics31.3.2026 10:00:00 CEST | Press release
Unified data and a total portfolio view across public and private assets improves transparency, risk oversight, and investment decision-making Bloomberg and Clearwater Analytics (NYSE: CWAN) today announced that BarmeniaGothaer Asset Management AG, one of Germany’s top 10 insurance asset managers managing more than 50 billion euros in assets, has gone live on Bloomberg’s buy-side solutions and has selected Clearwater Analytics as its middle- and back-office management platform, including accounting and data management, completing its front-to-back investment transformation across the organization. The merger of Barmenia and Gothaer in 2024 has created the opportunity to successfully unite two distinct technology and data environments, thereby advancing investment management to a new level. By integrating Bloomberg’s buy-side solutions and Clearwater Analytics into its operations, BarmeniaGothaer Asset Management AG is creating a future-proof investment management workflow that meets th
TREASoURcE Final Conference: 14 April 2026, Brussels – Circular Systemic Solutions: From Demos to Deployment31.3.2026 09:32:00 CEST | Press release
The EU-funded project brings policymakers, industry and cities together to discuss how circular economy solutions can scale beyond pilots. The EU-funded TREASoURcE project will present its key results and policy messages at the Final Conference on 14 April 2026 in Brussels, bringing together policymakers, industry representatives, researchers, cities and civil society actors from across Europe. The full-day conference focuses on how circular economy solutions can move from pilot projects to broader deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331360899/en/ Join us in Brussels for the TREASoURcE Final Conference on circular solutions. Over four years, TREASoURcE has developed and tested scalable circular solutions across three value chains: plastics, batteries, and biobased side and waste streams. From demonstrations to deployment: addressing Europe’s scaling challenge The final conference responds to one of
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 09:00:00 CEST | Press release
Breaking the heat barrier: Tempo advances towards commercial rollout of continuously delivered electrified industrial heat at up to 1,200°C Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management31.3.2026 09:00:00 CEST | Press release
Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares' platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on a powerful rules engine that enables intuitive compensation plan design, giving organizations the flexibility to model incentive structures in a fully self-service environment, unlocking new possibilities for incentive management at scale. Supporting more than 40 organizations, including Nespresso, TheFork, and Rakuten, Amalia provides real-time visibility into performance and incentive data, enabling companies to operate complex compensation programs with greater control and efficiency. “From day one, our focus has been to bring clarity to performance-based comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom